The agency warned that less surveillance would particularly harm efforts to detect new COVID variants and undermine a potential response
A Covid working group of NTAGI will review this week data of SII anti-coronavirus jab Covovax to decide whether it can be included vaccination programme for inoculating those aged 12 years and above
The test positivity rate was zero and the fatality and recovery rates were 1.18 per cent and 98.82 per cent, respectively.
The US Food and Drug Administration has approved a fifth Covid-19 booster shot of Pfizer-BioNTech or the Moderna for people aged over 50 and some immunocompromised individuals.
India has so far administered 1,838,241,743 vaccine doses. That is 4272.67 per cent of its total caseload, and 131.05 per cent of its population
The Covid-19 mortality rate in the district is 1.67 per cent
The US continues to be the worst-hit country with the world's highest number of cases and deaths
The move will increase protection for these vulnerable groups against severe disease from Covid-19, Xinhua news agency quoted the CDC as saying.
Amid growing resentment over the stringent measures towards the zero-Covid policy by the authorities, the Chinese public has been taking to social media platforms to express their frustration
The variant has been steadily rising in proportion due to its increased transmissibility compared to the original Omicron strain, Xinhua news agency reported.
FDA authorises another booster dose of the Pfizer or Moderna Covid vaccine for people age 50 and up
As many as 17,846 samples were tested in the last 24 hours
Accordingly, all states/UTs report cases and deaths to the health ministry and the same is also put in public domain on a regular basis
The National Technical Advisory Group on Immunisation (NTAGI) needs adequate scientific data to make a recommendation on mixing of COVID-19 vaccines, the government said on Tuesday. The Central Drugs Standard Control Organization (CDSCO) has granted permission to the Christian Medical College, Vellore to conduct phase-IV study with Covishield and Covaxin to compare immunogenicity of mixed vaccine regimen and to Bharat Biotech for phase-2 clinical trial to evaluate the immunogenicity and safety of Covaxin with BBV154 (Adenoviral Intranasal COVID-19 vaccine), Minister of State for Health Bharati Pravin Pawar said. "Adequate scientific data is required for NTAGI to make a recommendation on mixing of COVID-19 vaccines, at present this information is not available," Pawar said in a written reply in the Rajya Sabha. She was responding to question on whether the government is considering mixing of COVID-19 vaccines based on heterologous strategies conducted earlier for other diseases, to .
While Shanghai's caseload remains modest by global standards, the city has become a testing ground for China's 'zero-Covid' strategy
India has so far administered 1,835,390,499 vaccine doses. That is 4266.16 per cent of its total caseload, and 130.85 per cent of its population
A report of the state public health department said that 68.4 per cent of all whole-genome sequenced samples were of the BA.2 variant while 15.2 per cent were of the BA.1.1 variant.
India accounts for the second highest caseload
Over 12.8 million children have tested positive for Covid-19 since the onset of the pandemic in the country, according to the report.
World stocks were largely flat, holding their ground in the face of another brutal selloff in major bond markets